#Securities Fraud #Berger Montague #Switzerland #Zug #MoonLake Technologies

MoonLake Immunotherapeutics and the Allegations of Fraud

A significant legal challenge is unfolding for MoonLake Immunotherapeutics, a clinical-stage biotechnology firm based in Zug, Switzerland. On October 27, 2025, the national plaintiffs' law firm Berger Montague PC announced a class action lawsuit aimed at the company on behalf of investors who purchased shares between March 10, 2024, and September 29, 2025. This class action arises from serious allegations of securities fraud that question the integrity of the company's communications regarding their key drug candidate, sonelokimab (SLK).

Background

MoonLake emerged as an innovative biotechnology entity focusing on advanced therapies for skin conditions. Their lead candidate, SLK, had been touted as a significant advancement in treatment options. Promoted as a Nanobody structure, it was claimed to provide superior clinical benefits compared to traditional monoclonal antibodies, including the FDA-approved drug BIMZELX. As the company pushed SLK into clinical testing, expectations soared among investors and analysts alike, raising hopes for groundbreaking results in treating various dermatological issues.

However, troubles began to surface following the announcement of Phase 3 clinical trial results on September 28, 2025. The findings reportedly indicated SLK’s lack of efficacy when compared to BIMZELX. Analysts characterized the outcome as “disastrous,” leading MoonLake’s stock to plummet dramatically by nearly 90%—equating to a staggering loss of $55.75 per share in the aftermath of the announcement. These steep declines raised alarm bells among investors, who felt misled by the company’s previous optimistic declarations regarding SLK’s potential effectiveness.

Allegations and Legal Actions

The lawsuit claims that MoonLake and its executives are guilty of disseminating false and misleading statements about SLK, raising serious ethical concerns about their corporate practices. Investors who bought shares within the designated class period have been urged to consider their legal options, with the potential to be appointed as lead plaintiffs in the case. The deadline for interested investors to take action is December 15, 2025.

Investor Support

For those looking to understand their legal rights in this reactive environment, Berger Montague offers avenues for assistance. Interested investors have the opportunity to reach out to attorneys Andrew Abramowitz or Caitlin Adorni, who specialize in securities fraud litigation. Their contact details have been made available for those seeking to explore their options further.

About the Firm

Founded in 1970, Berger Montague has established itself as a preeminent player in the realm of securities class action litigation. With offices across multiple states and a wealth of experience representing both individual and institutional investors, the firm continues to advocate vigorously for those alleging securities fraud. With the current lawsuit against MoonLake Immunotherapeutics, Berger Montague aims to hold the company accountable for its allegedly deceptive practices.

The unfolding events surrounding MoonLake Immunotherapeutics serve as a stark reminder of the risks and responsibilities in the high-stakes world of biotechnology investments. As the litigation progresses, stakeholders will be watching closely to see how corporate accountability and investor rights are upheld within this volatile sector.